Xvivo Perfusion ABXVIPF -1.32%91 ROA % is 5.99% as of Mar. 2026, which is 450% above its 10-year median of 1.09. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 61.96% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Xvivo Perfusion AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $15.58 Mil.
Xvivo Perfusion AB's average Total Assets over the quarter that ended in Mar. 2026 was $260.23 Mil. Therefore, Xvivo Perfusion AB's annualized ROA % for the quarter that ended in Mar. 2026 was 5.99%.
The historical rank and industry rank for Xvivo Perfusion AB's ROA % or its related term are showing as below:
XVIPF'
s ROA % Range Over the Past 10 Years
Min: -4.9 Med: 1.09 Max: 7.49
Current: 3.1
During the past 13 years, Xvivo Perfusion AB's highest ROA % was 7.49%. The lowest was -4.90%. And the median was 1.09%.
XVIPF's ROA % is ranked better than 61.96% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.56
vs XVIPF: 3.10
Xvivo Perfusion AB (OTCPK:XVIPF) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Xvivo Perfusion AB ROA % Related Terms
Xvivo Perfusion AB ROA % Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's ROA % distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Xvivo Perfusion AB (XVIPF) has a ROA % of 5.99% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Xvivo Perfusion AB and its competitors. This is 450% above median its historical median of 1.09. According to the industry distribution chart, Xvivo Perfusion AB ranks #326 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 38%.
Is Xvivo Perfusion AB's ROA % too high?
Xvivo Perfusion AB's current ROA % of 5.99% is 450% above median its 10-year median of 1.09. The Medical Devices & Instruments industry median ROA % is 0.56. Xvivo Perfusion AB's value of 5.99% is 969.6% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #326 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #326 out of 857 companies for ROA %. This puts Xvivo Perfusion AB in the upper half of its industry. The industry median ROA % is 0.56. Xvivo Perfusion AB's value of 5.99% is 969.6% above this benchmark. While the company's 10-year median is 1.09 vs. the industry median of 0.56, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.56, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current ROA % of 5.99% is 969.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current ROA % is 5.99%, which is 450% above median its own 10-year median of 1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current ROA % is 5.99%, which is 450% above median its 10-year median of 1.09 and 969.6% above the Medical Devices & Instruments industry median of 0.56. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current ROA % is 5.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
ROA %: 5.99% (450% above median its 10-year median of 1.09)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 969.6% above the Medical Devices & Instruments median (#326 of 857)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
